J&J, Bris­tol My­ers race to am­pli­fy CAR-T man­u­fac­tur­ing to meet la­bel ex­pan­sion in mul­ti­ple myelo­ma

John­son & John­son and Bris­tol My­ers Squibb are in­di­vid­u­al­ly gear­ing up their lentivi­ral pro­duc­tion and CAR-T prod­uct ca­pac­i­ties fol­low­ing their re­cent la­bel ex­pan­sions in mul­ti­ple myelo­ma.

J&J, along­side part­ner Leg­end Biotech, has its eyes on dou­bling its Carvyk­ti ca­pac­i­ty by the end of 2024, said Kim­ber­ly Loun­ds Fos­ter, J&J vice pres­i­dent for ad­vanced ther­a­pies sup­ply chain, in an in­ter­view with End­points News. Carvyk­ti has been ad­min­is­tered in over 2,700 pa­tients so far, she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER